Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
- Autores
- Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; Montoro, Claudia Calle; Alfaro, María Agustina; Roldán, Brian M.; Gómez Vara, Andrea B.; Giorgis, Pamela; Ezquer, Roberto Alejandro; Crespo Rocha, María G; Reyes Gómez, Camila R.; de Los Ángeles Correa, Mária; Rosemffet, Marcos G.; Abarza, Virginia Carrizo; Pellet, Santiago Catalan; Perandones, Miguel; Reimundes, Cecilia; Longueira, Yesica Soledad; Turk, Gabriela Julia Ana; Quiroga, María Florencia; Laufer, Natalia Lorna; Quintana, Rosana Maris; de la Vega, María Celina; Kreplak, Nicolás; Pifano, Marina; Maid, Pablo; Pons Estel, Guillermo J.; Citera, Gustavo
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.
Fil: Isnardi, Carolina A.. No especifíca;
Fil: Cerda, Osvaldo L.. No especifíca;
Fil: Landi, Margarita. Austral University Hospital; Liberia
Fil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Schneeberger, Emilce E.. No especifíca;
Fil: Montoro, Claudia Calle. Austral University Hospital; Liberia
Fil: Alfaro, María Agustina. No especifíca;
Fil: Roldán, Brian M.. No especifíca;
Fil: Gómez Vara, Andrea B.. No especifíca;
Fil: Giorgis, Pamela. No especifíca;
Fil: Ezquer, Roberto Alejandro. No especifíca;
Fil: Crespo Rocha, María G. No especifíca;
Fil: Reyes Gómez, Camila R.. No especifíca;
Fil: de Los Ángeles Correa, Mária. No especifíca;
Fil: Rosemffet, Marcos G.. No especifíca;
Fil: Abarza, Virginia Carrizo. No especifíca;
Fil: Pellet, Santiago Catalan. Austral University Hospital; Liberia
Fil: Perandones, Miguel. No especifíca;
Fil: Reimundes, Cecilia. Austral University Hospital; Liberia
Fil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quintana, Rosana Maris. No especifíca;
Fil: de la Vega, María Celina. No especifíca;
Fil: Kreplak, Nicolás. No especifíca;
Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Maid, Pablo. Austral University Hospital; Liberia
Fil: Pons Estel, Guillermo J.. No especifíca;
Fil: Citera, Gustavo. No especifíca; - Materia
-
ARGENTINA
COVID-19
RHEUMATOID ARTHRITIS
SARS-COV-2
VACCINES - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/212994
Ver los metadatos del registro completo
id |
CONICETDig_74438af6bd4f84fb6051927947950ded |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/212994 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based VaccinesIsnardi, Carolina A.Cerda, Osvaldo L.Landi, MargaritaCruces, Leonel HernánSchneeberger, Emilce E.Montoro, Claudia CalleAlfaro, María AgustinaRoldán, Brian M.Gómez Vara, Andrea B.Giorgis, PamelaEzquer, Roberto AlejandroCrespo Rocha, María GReyes Gómez, Camila R.de Los Ángeles Correa, MáriaRosemffet, Marcos G.Abarza, Virginia CarrizoPellet, Santiago CatalanPerandones, MiguelReimundes, CeciliaLongueira, Yesica SoledadTurk, Gabriela Julia AnaQuiroga, María FlorenciaLaufer, Natalia LornaQuintana, Rosana Marisde la Vega, María CelinaKreplak, NicolásPifano, MarinaMaid, PabloPons Estel, Guillermo J.Citera, GustavoARGENTINACOVID-19RHEUMATOID ARTHRITISSARS-COV-2VACCINEShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.Fil: Isnardi, Carolina A.. No especifíca;Fil: Cerda, Osvaldo L.. No especifíca;Fil: Landi, Margarita. Austral University Hospital; LiberiaFil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Schneeberger, Emilce E.. No especifíca;Fil: Montoro, Claudia Calle. Austral University Hospital; LiberiaFil: Alfaro, María Agustina. No especifíca;Fil: Roldán, Brian M.. No especifíca;Fil: Gómez Vara, Andrea B.. No especifíca;Fil: Giorgis, Pamela. No especifíca;Fil: Ezquer, Roberto Alejandro. No especifíca;Fil: Crespo Rocha, María G. No especifíca;Fil: Reyes Gómez, Camila R.. No especifíca;Fil: de Los Ángeles Correa, Mária. No especifíca;Fil: Rosemffet, Marcos G.. No especifíca;Fil: Abarza, Virginia Carrizo. No especifíca;Fil: Pellet, Santiago Catalan. Austral University Hospital; LiberiaFil: Perandones, Miguel. No especifíca;Fil: Reimundes, Cecilia. Austral University Hospital; LiberiaFil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quintana, Rosana Maris. No especifíca;Fil: de la Vega, María Celina. No especifíca;Fil: Kreplak, Nicolás. No especifíca;Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Maid, Pablo. Austral University Hospital; LiberiaFil: Pons Estel, Guillermo J.. No especifíca;Fil: Citera, Gustavo. No especifíca;J Rheumatol Publ Co2022-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/212994Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-13890315-162XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3899/jrheum.220469info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:05Zoai:ri.conicet.gov.ar:11336/212994instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:05.258CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
title |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
spellingShingle |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines Isnardi, Carolina A. ARGENTINA COVID-19 RHEUMATOID ARTHRITIS SARS-COV-2 VACCINES |
title_short |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
title_full |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
title_fullStr |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
title_full_unstemmed |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
title_sort |
Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines |
dc.creator.none.fl_str_mv |
Isnardi, Carolina A. Cerda, Osvaldo L. Landi, Margarita Cruces, Leonel Hernán Schneeberger, Emilce E. Montoro, Claudia Calle Alfaro, María Agustina Roldán, Brian M. Gómez Vara, Andrea B. Giorgis, Pamela Ezquer, Roberto Alejandro Crespo Rocha, María G Reyes Gómez, Camila R. de Los Ángeles Correa, Mária Rosemffet, Marcos G. Abarza, Virginia Carrizo Pellet, Santiago Catalan Perandones, Miguel Reimundes, Cecilia Longueira, Yesica Soledad Turk, Gabriela Julia Ana Quiroga, María Florencia Laufer, Natalia Lorna Quintana, Rosana Maris de la Vega, María Celina Kreplak, Nicolás Pifano, Marina Maid, Pablo Pons Estel, Guillermo J. Citera, Gustavo |
author |
Isnardi, Carolina A. |
author_facet |
Isnardi, Carolina A. Cerda, Osvaldo L. Landi, Margarita Cruces, Leonel Hernán Schneeberger, Emilce E. Montoro, Claudia Calle Alfaro, María Agustina Roldán, Brian M. Gómez Vara, Andrea B. Giorgis, Pamela Ezquer, Roberto Alejandro Crespo Rocha, María G Reyes Gómez, Camila R. de Los Ángeles Correa, Mária Rosemffet, Marcos G. Abarza, Virginia Carrizo Pellet, Santiago Catalan Perandones, Miguel Reimundes, Cecilia Longueira, Yesica Soledad Turk, Gabriela Julia Ana Quiroga, María Florencia Laufer, Natalia Lorna Quintana, Rosana Maris de la Vega, María Celina Kreplak, Nicolás Pifano, Marina Maid, Pablo Pons Estel, Guillermo J. Citera, Gustavo |
author_role |
author |
author2 |
Cerda, Osvaldo L. Landi, Margarita Cruces, Leonel Hernán Schneeberger, Emilce E. Montoro, Claudia Calle Alfaro, María Agustina Roldán, Brian M. Gómez Vara, Andrea B. Giorgis, Pamela Ezquer, Roberto Alejandro Crespo Rocha, María G Reyes Gómez, Camila R. de Los Ángeles Correa, Mária Rosemffet, Marcos G. Abarza, Virginia Carrizo Pellet, Santiago Catalan Perandones, Miguel Reimundes, Cecilia Longueira, Yesica Soledad Turk, Gabriela Julia Ana Quiroga, María Florencia Laufer, Natalia Lorna Quintana, Rosana Maris de la Vega, María Celina Kreplak, Nicolás Pifano, Marina Maid, Pablo Pons Estel, Guillermo J. Citera, Gustavo |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
ARGENTINA COVID-19 RHEUMATOID ARTHRITIS SARS-COV-2 VACCINES |
topic |
ARGENTINA COVID-19 RHEUMATOID ARTHRITIS SARS-COV-2 VACCINES |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response. Fil: Isnardi, Carolina A.. No especifíca; Fil: Cerda, Osvaldo L.. No especifíca; Fil: Landi, Margarita. Austral University Hospital; Liberia Fil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Schneeberger, Emilce E.. No especifíca; Fil: Montoro, Claudia Calle. Austral University Hospital; Liberia Fil: Alfaro, María Agustina. No especifíca; Fil: Roldán, Brian M.. No especifíca; Fil: Gómez Vara, Andrea B.. No especifíca; Fil: Giorgis, Pamela. No especifíca; Fil: Ezquer, Roberto Alejandro. No especifíca; Fil: Crespo Rocha, María G. No especifíca; Fil: Reyes Gómez, Camila R.. No especifíca; Fil: de Los Ángeles Correa, Mária. No especifíca; Fil: Rosemffet, Marcos G.. No especifíca; Fil: Abarza, Virginia Carrizo. No especifíca; Fil: Pellet, Santiago Catalan. Austral University Hospital; Liberia Fil: Perandones, Miguel. No especifíca; Fil: Reimundes, Cecilia. Austral University Hospital; Liberia Fil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Quintana, Rosana Maris. No especifíca; Fil: de la Vega, María Celina. No especifíca; Fil: Kreplak, Nicolás. No especifíca; Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Maid, Pablo. Austral University Hospital; Liberia Fil: Pons Estel, Guillermo J.. No especifíca; Fil: Citera, Gustavo. No especifíca; |
description |
Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/212994 Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-1389 0315-162X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/212994 |
identifier_str_mv |
Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-1389 0315-162X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3899/jrheum.220469 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
J Rheumatol Publ Co |
publisher.none.fl_str_mv |
J Rheumatol Publ Co |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269736076836864 |
score |
13.13397 |